论文部分内容阅读
目的对原发性肠道非霍奇金淋巴瘤穿孔患者的临床及病理特征、诊治、预后进行探讨。方法回顾性分析1999年1月-2008年12月诊治的17例原发性肠道非霍奇金淋巴瘤穿孔患者的临床资料。结果 B细胞型9例,T细胞型8例。17例原发肠道非霍奇金淋巴瘤穿孔患者的穿孔部位:大肠7例,小肠7例,回盲部3例。所有患者均行手术治疗。除2例穿孔前行化疗的患者以外,其余患者术前均未明确诊断。有14例获得随访结果,6例术后3个月内死亡,术后接受化疗者7例,1、2、3年生存率分别为41.2%、23.6%、11.7%,仅1例生存期超过5年。结论原发性肠道非霍奇金淋巴瘤穿孔术前诊断困难,预后极差。
Objective To investigate the clinical and pathological features, diagnosis, treatment and prognosis of patients with primary intestinal non-Hodgkin’s lymphoma perforation. Methods The clinical data of 17 patients with primary non-Hodgkin’s lymphoma perforation who were diagnosed and treated from January 1999 to December 2008 were analyzed retrospectively. Results B cell type in 9 cases, T cell type in 8 cases. Perforation sites of 17 patients with primary intestinal non-Hodgkin’s lymphoma perforation: 7 cases of large intestine, 7 cases of small intestine and 3 cases of ileocecal lymph nodes. All patients underwent surgical treatment. All the patients except the two patients with perforation chemotherapy before surgery had no definite diagnosis. Fourteen patients were followed up, 6 patients died within 3 months after operation, and 7 patients underwent chemotherapy. The 1, 2 and 3 year survival rates were 41.2%, 23.6% and 11.7%, respectively. Only 1 patient survived 5 years. Conclusion Primary intestinal non-Hodgkin’s lymphoma is difficult to diagnose before perforation, and its prognosis is very poor.